Pfizer is expected to announce its second-quarter results next month, and analysts predict a single-digit drop in the company ...

Analysts expect Johnson & Johnson to report an earnings per share (EPS) of $2.67. Johnson & Johnson bulls will hope to hear ...

Tech giants Alphabet and Tesla are set to report earnings this week. Investors should keep a close eye on economic reports coming giving this week. See more here.

Our Top 5 Analyst Questions Pfizer’s Q1 Earnings Call Vamil Divan (Guggenheim): Asked about Pfizer’s ability to maintain and grow its dividend amid tariff uncertainty and cash flow pressure.

Pfizer (PFE) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of ...

Pfizer's cost-cutting boosts earnings despite revenue miss. Discover its growth strategy, strong drug portfolio & potential 29% upside. Click here to read.

Pfizer PFE is likely to encounter several headwinds in the next couple of years that can hurt its sales and profits, the first being declining sales of COVID products, Comirnaty and Paxlovid.

Pfizer: Competitive Advantages Still Exist, but Signs of Erosion Lead Us to Lower Our Valuation We’ve also reduced the firm’s moat rating from wide to narrow.